• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avenue Therapeutics Inc. (Amendment)

    2/14/23 11:22:58 AM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXI alert in real time by email
    SC 13G/A 1 tm235037d21_sc13ga.htm SC 13G/A

     

    CUSIP No: 05360L304

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Avenue Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    05360L304

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 05360L304

     

    (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc. 

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    251,011

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    251,011

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    251,011

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 05360L304

     

    (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    251,011

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    251,011

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    251,011

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 05360L304

     

    Item 1.

     

    (a) Name of Issuer

     

    Avenue Therapeutics, Inc. (the “Company”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e) CUSIP Number

     

    05360L304

      

     

     

     

    CUSIP No: 05360L304

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Current Report on Form 8-K, filed on February 2, 2023, indicates there were 4,779,272 Shares outstanding as of November 10, 2022.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 05360L304

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 05360L304

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2023

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which was previously filed   Name: Brian Sopinsky
      Title: Secretary
         
         
    By: /s/ Brian Sopinsky      
    Name: Brian Sopinsky    
    Title: Secretary    

     

     

     

     

     

    CUSIP No: 05360L304

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

    *Previously filed

     

     

     

    Get the next $ATXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

      MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. "We have generated considerable momentum this past quarter in advancing our pipeline of innovative treatments for neurologic diseases," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. "AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet m

      11/14/24 4:05:03 PM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

      MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here. About Avenue TherapeuticsAvenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focus

      10/9/24 8:30:59 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avenue Therapeutics to Participate in Upcoming Investor Conferences

      MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings The H.C. Wainwright

      9/3/24 8:30:35 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Leadership Updates

    Live Leadership Updates

    See more
    • Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

      MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease, today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors. Lindsay A. Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer and Board Member of Urica, said, "We ar

      10/3/22 8:00:00 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Financials

    Live finance-specific insights

    See more
    • Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

      MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co

      3/25/24 8:30:00 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

      Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

      8/14/23 4:01:50 PM ET
      $ATXI
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Fortress Biotech, Inc. was granted 33,724 shares, increasing direct ownership by 11% to 328,524 units (SEC Form 4)

      4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      4/2/25 4:05:13 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Fortress Biotech, Inc. claimed ownership of 294,800 shares (SEC Form 3)

      3 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      1/3/25 4:21:27 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Herskowitz Neil sold $46 worth of shares (23 units at $2.00), decreasing direct ownership by 19% to 97 units (SEC Form 4)

      4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      12/3/24 4:30:17 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

      SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      11/15/24 4:05:50 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avenue Therapeutics Inc.

      SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      11/14/24 3:22:45 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Avenue Therapeutics Inc. (Amendment)

      SC 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      5/2/24 4:02:02 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avenue Therapeutics Inc.

      10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

      5/15/25 4:07:15 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

      4/30/25 4:30:25 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.

      SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      4/2/25 5:00:06 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

      4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      10/1/24 4:15:13 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care